OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	190.58B +74.8%
Revenue (ttm)	87.16B +6.4%
Net Income	11.36B +10.2%
EPS	730.00 +8.1%
Shares Out	17.65M
PE Ratio	14.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,320,162
Average Volume	994,957
Open	14,180
Previous Close	13,770
Day's Range	9,900 - 14,860
52-Week Range	5,610 - 20,750
Beta	0.45
RSI	44.97
Earnings Date	Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.